AJTMH ASTMH MEMBERSHIP INFORMATION: astmh@astmh.org
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am. J. Trop. Med. Hyg., 17(5), 1968, pp. 733-736
Copyright © 1968 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bezjak, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bezjak, B.

A Clinical Trial of Thiabendazole in Strongyloidiasis

Branko Bezjak
Hospital for Infectious Diseases, Zagreb, Yugoslavia

A clinical trial of thiabendazole (Mintezol®, Merck, Sharp & Dohme) in the treatment of 30 cases of strongyloidiasis was done. Clinical, hematologic, and parasitologic criteria were used to determine the effectiveness of treatment. Twenty-nine patients were followed for up to 6 months; most were examined two or three times. In all patients, Strongyloides infection was eradicated by a single course of treatment, 25 mg per kilogram of body weight, twice daily on 2 successive days. In all but two patients, clinical symptoms diminished or disappeared. Eosinophilia demonstrated before treatment in 23 patients (mean eosinophil rate, 15.0%) persisted 6 months later in only three patients (mean rate, 7.0%).

Side-effects of the drug (most frequently, nausea) were recorded in 16 patients. In most instances all side-effects were mild and without much clinical significance.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1968 by the American Society of Tropical Medicine and Hygiene.